NEW FILINGS<\/p>\n
Company: Snap One Holdings Corp
\nSymbol: SNPO (Nasdaq)
\nDescription: Snap One powers smart living by enabling professional integrators to deliver seamless experiences in the connected homes and small businesses where people live, work and play.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Morgan Stanley, J.P. Morgan, Jefferies, UBS Investment Bank \u200b
\nCo-Manager(s): BMO Capital Markets,Raymond James, Truist Securities, William Blair,\u200b Drexel Hamilton, Penserra Securities, R. Seelaus & Co., Siebert Williams Shank
\nLink to Prospectus: Filed: 7-2-21
\nListed Cash Raise: $100m<\/p>\n
Company: Dole, Inc.
\nSymbol: DOLE (NYSE)
\nDescription: They are the premier global leader in fresh fruits and vegetables.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, Deutsche Bank Securities, Davy, BofA Securities, BMO Capital Markets, Rabo Securities, Stephens Inc.
\nLink to Prospectus: Filed: 7-2-21
\nListed Cash Raise: $100m<\/p>\n
Company: WCG Clinical, Inc.
\nSymbol: WCGC (Nasdaq)
\nDescription: They believe they are a leading provider of clinical trial solutions, focused on providing solutions that are designed to measurably improve the quality and efficiency of clinical research, stimulate growth and foster compliance.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, Morgan Stanley, BofA Securities, Barclays, Jefferies, William Blair, BMO Capital Markets, UBS Investment Bank, SVB Leerink HSBC
\nLink to Prospectus: Filed: 7-1-21
\nListed Cash Raise: $100m<\/p>\n
Company: Caribou Biosciences, Inc.
\nSymbol: CRBU (Nasdaq)
\nDescription: They are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, CRISPR hybrid RNA-DNA, or chRDNA, pronounced \u201cchardonnay,\u201d toward the development of next-generation, genome-edited cell therapies.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: BofA Securities, Citigroup, SVB Leerink
\nLink to Prospectus: Filed: 7-1-21
\nListed Cash Raise: $100m<\/p>\n
Company: Riskified, Ltd.
\nSymbol: RSKD (Nasdaq)
\nDescription: They have built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, JP Morgan, Credit Suisse
\nCo-Manager(s): Barclays, KeyBanc Capital Markets, Piper Sandler, Truist Securities, William Blair
\nLink to Prospectus: Filed: 7-1-21
\nListed Cash Raise: $100m<\/p>\n
Company: Robinhood Markets, Inc
\nSymbol: HOOD (Nasdaq)
\nDescription: They are creating a modern financial services platform for everyone, regardless of their wealth, income or background.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, JP Morgan, Barclays, Citigroup, Wells Fargo, Mizuho Securities
\nCo-Manager(s): JMP Securities, KeyBanc Capital Markets, Piper Sandler, Rosenblatt Securities, BMO Capital Markets, BTIG, Santander, Academy Securities, Loop Capital Markets, Ramirez & Co. Siebert Williams Shank
\nLink to Prospectus: Filed: 7-1-21
\nListed Cash Raise: $100m<\/p>\n
Company: Healthcare Royalty, Inc
\nSymbol: HCRX (Nasdaq)
\nDescription: They are the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, Citigroup, Credit Suisse, Jefferies, Cowen, SVB Leerink
\nCo-Manager(s): Truist Securities, BMO Capital Markets, Stifel, Raymond James
\nLink to Prospectus: Filed: 7-1-21
\nListed Cash Raise: $100m<\/p>\n
Company: Absci Corporation
\nSymbol: ABSI (Nasdaq)
\nDescription: They enable the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: J.P. Morgan, Credit Suisse, BofA Securities, Cowen, Stifel
\nLink to Prospectus: Filed: 6-30-21
\nListed Cash Raise: $100m<\/p>\n
Company: Outbrain, Inc.
\nSymbol: OB (Nasdaq)
\nDescription: Outbrain is a leading recommendation platform powering the open web. Founded in 2006, they pioneered the online content recommendation category.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Citigroup, Jefferies, Barclays, Evercore
\nCo-Manager(s): JMP Securities, Needham, LUMA Securities
\nLink to Prospectus: Filed: 6-29-21
\nListed Cash Raise: $100m<\/p>\n
Company: Duolingo, Inc.
\nSymbol: DUOL (Nasdaq)
\nDescription: Duolingo is the leading mobile learning platform globally.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, Allen & Co., BofA Securities, Barclays, Evercore ISI, William Blair
\nCo-Manager(s): KeyBanc Capital, JMP Securities, Piper Sandler Raymond James
\nLink to Prospectus: Filed: 6-28-21
\nListed Cash Raise: $100m<\/p>\n
Company: Elicio Therapeutics, Inc.
\nSymbol: ELTX (NASDAQ)
\nDescription: They are a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: BTIG, Oppenheimer
\nCo-Manager(s): National Securities
\nLink to Prospectus: Filed: 6-28-21
\nListed Cash Raise: $10m<\/p>\n
Company: Instructure Holdings Inc.
\nSymbol: INST (NYSE)
\nDescription: Their learning platform delivers the elements that leaders, teachers, and learners need \u2013 a next-generation LMS, robust assessments for learning, actionable analytics, and engaging, dynamic content.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Morgan Stanley, JP Morgan, Citigroup, Jefferies, Macquarie Capital
\nCo-Manager(s): Baird, BTIG, Raymond James, Truist Securities, William Blair
\nLink to Prospectus: Filed: 6-28-21
\nListed Cash Raise: $100m<\/p>\n
Company: VTEX
\nSymbol: VTEX (NYSE)
\nDescription: VTEX provides a software-as-a-service digital commerce platform for enterprise brands and retailers.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: J.P. Morgan, Goldman Sachs, BofA Securities, KeyBanc Capital Markets, Morgan Stanley, Ita\u00fa BBA
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Vividion Therapeutics, Inc.
\nSymbol: VVID (NASDAQ)
\nDescription: They are a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for cancers and immune disorders.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: JP Morgan, BofA Securities, Jefferies
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Gambling.com Group Limited
\nSymbol: GAMB (NASDAQ)
\nDescription: They are a multi-award-winning performance marketing company and a leading provider of digital marketing services active exclusively in the online gambling industry based on December 31, 2020 revenue.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Jefferies
\nCo-Manager(s): Stifel, Truist
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Dynacure S.A.
\nSymbol: DYCU (NASDAQ)
\nDescription: They are a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: J.P. Morgan, BofA Securities, Wells Fargo Securities
\nCo-Manager: Needham & Company
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Erasca, Inc.
\nSymbol: ERAS (NASDAQ)
\nDescription: They are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS\/MAPK pathway-driven cancers.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Xponential Fitness, Inc.
\nSymbol: XPOF (NYSE)
\nDescription: Xponential Fitness is a curator of leading boutique fitness brands across multiple verticals.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: BofA Securities, Jefferies, Morgan Stanley
\nCo-Manager(s): Guggenheim Securities, Citigroup, Piper Sandler, Baird, Raymond James
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Candel Therapeutics, Inc.
\nSymbol: CADL (NASDAQ)
\nDescription: They are a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Jefferies, Credit Suisse, BMO Capital Markets, UBS Investment Bank
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: CS Disco, Inc.
\nSymbol: LAW
\nDescription: DISCO provides a cloud-native, artificial intelligence-powered legal solution that simplifies ediscovery, legal document review and case management for enterprises, law firms, legal services providers and governments.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: JP Morgan, BofA Securities, Citigroup, Jefferies
\nCo-Manager(s): Canaccord Genuity, Cowen, Needham, Stifel, Loop Capital
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Rapid Micro Biosystems, Inc.
\nSymbol: RPID (NASDAQ)
\nDescription: They are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: JP Morgan, Morgan Stanley, Cowen, Stifel
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Imago BioSciences, Inc.
\nSymbol: IMGO (NASDAQ)
\nDescription: They are a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Jefferies, Cowen, Stifel, Guggenheim Securities
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Zenvia Inc.
\nSymbol: ZENV
\nDescription: They empower companies to transform their existing customer communications from non-scalable, physical and impersonal interactions into highly scalable, digital first and hyper contextualized customer journey experiences.
\nShares: 12.9 million
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, Itau BBA, UBS Investment Bank, Bradesco BBI, XP Investimentos
\nLink to Prospectus: Filed: 6-25-21
\nIPO Postponed in May 2021<\/p>\n
Company: Perspectum Group plc
\nSymbol: SCAN (NASDAQ)
\nDescription: They are a leading commercial-stage precision health company focused on democratizing high-quality care globally through the use of our proprietary digital technologies that enable healthcare providers to provide better care for patients.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Citigroup, Barclays, Stifel, Canaccord Genuity
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $75m<\/p>\n
Company: Manycore Tech Inc.
\nSymbol: KOOL (NASDAQ)
\nDescription: Their platform empowers the creation, sharing and implementation of millions of design ideas, bringing people closer to their dream homes and spaces.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Morgan Stanley, JP Morgan, CICC
\nCo-Manager(s): China Securities International, FUTU
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
Company: Zevia PBC, Inc.
\nSymbol: ZVIA (NYSE)
\nDescription: They are a high-growth beverage company that is disrupting the liquid refreshment beverage industry through delicious and refreshing, zero calorie, zero sugar, naturally sweetened beverages that are all Non-GMO Project Verified.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, BofA Securities, Morgan Stanley
\nCo-Manager(s): Stephens, BMO, Wells Fargo
\nLink to Prospectus: Filed: 6-25-21
\nListed Cash Raise: $100m<\/p>\n
UPDATED TERMS<\/p>\n
Company: LinkDoc Technology Limited
\nSymbol: LDOC (Nasdaq)
\nDescription: They are a leading data-driven and AI-enabled healthcare technology company in terms of first-mover in cultivating high-quality medical data assets with the largest set of China oncology cohorts, according to Frost & Sullivan.
\nShares: 10.825 million ADSs
\nPrice Range: $17.50-$19.50
\nMarket Cap: $1.3b-$1.45b
\nTrade Date: Friday, 7\/9
\nUnderwriters: Morgan Stanley, BofA Securities, CICC
\nCo-Manager(s): Tiger Brokers, Snowball
\nLink To Prospectus: Terms Added: 7-1-21<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":12986,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[2058,1536],"tags":[],"class_list":["post-20259","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-spotlight","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/20259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=20259"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/20259\/revisions"}],"predecessor-version":[{"id":20260,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/20259\/revisions\/20260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media\/12986"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=20259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=20259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=20259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}